GEN

Improving CAR-T Cell Efficacy via New Manufacturing Process

At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
Business Wire

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
BioPharma Dive

Building a robust in-process testing plan for cell therapy manufacturing success

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for manufacturing that provide secure, real-time access to data, which can help ...
Nasdaq

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; Tevogen’s ability ...
EurekAlert!

Neutrophil extracellular traps license macrophage production of chemokines to facilitate CD8+ T cell infiltration in obstruction-induced renal fibrosis

NETs promote macrophage expression of T-cell chemokines and subsequently facilitate cytotoxic CD8+ T cell infiltration and granzyme B production, which drives kidney fibrosis in obstructive ...
Contract Pharma

Cellares, Stanford University Partner to Expand Automated Manufacturing Beyond T Cell Therapies

Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...